Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes.

Pizzolato G, Kaminski H, Tosolini M, Franchini DM, Pont F, Martins F, Valle C, Labourdette D, Cadot S, Quillet-Mary A, Poupot M, Laurent C, Ysebaert L, Meraviglia S, Dieli F, Merville P, Milpied P, Déchanet-Merville J, Fournié JJ.

Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11906-11915. doi: 10.1073/pnas.1818488116. Epub 2019 May 22.

PMID:
31118283
2.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ.

Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12.

PMID:
30862645
3.

DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.

Grgurevic S, Montilla-Perez P, Bradbury A, Gilhodes J, Queille S, Pelofy S, Bancaud A, Filleron T, Ysebaert L, Récher C, Laurent G, Fournié JJ, Cazaux C, Quillet-Mary A, Hoffmann JS.

Haematologica. 2018 Jun;103(6):1038-1046. doi: 10.3324/haematol.2017.174243. Epub 2018 Mar 22.

4.

Nurse-like cells promote CLL survival through LFA-3/CD2 interactions.

Boissard F, Tosolini M, Ligat L, Quillet-Mary A, Lopez F, Fournié JJ, Ysebaert L, Poupot M.

Oncotarget. 2016 Nov 26;8(32):52225-52236. doi: 10.18632/oncotarget.13660. eCollection 2017 Aug 8.

5.

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Betrian S, Ysebaert L, Heider KH, Delord JP, Fournié JJ, Quillet-Mary A.

Blood Cancer J. 2016 Nov 11;6(11):e496. doi: 10.1038/bcj.2016.106. No abstract available.

6.

3R gene expression in chronic lymphocytic leukemia reveals insight into disease evolution.

Grgurevic S, Berquet L, Quillet-Mary A, Laurent G, Récher C, Ysebaert L, Cazaux C, Hoffmann JS.

Blood Cancer J. 2016 Jun 3;6(6):e429. doi: 10.1038/bcj.2016.39. No abstract available.

7.

Nurse-like cells impact on disease progression in chronic lymphocytic leukemia.

Boissard F, Laurent C, Ramsay AG, Quillet-Mary A, Fournié JJ, Poupot M, Ysebaert L.

Blood Cancer J. 2016 Jan 15;6:e381. doi: 10.1038/bcj.2015.108. No abstract available.

8.

Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.

Ysebaert L, Laprévotte E, Klein C, Quillet-Mary A.

Blood Cancer J. 2015 Nov 13;5:e367. doi: 10.1038/bcj.2015.93. No abstract available.

9.

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients.

Boissard F, Fournié JJ, Quillet-Mary A, Ysebaert L, Poupot M.

Blood Cancer J. 2015 Oct 2;5:e355. doi: 10.1038/bcj.2015.74. No abstract available.

10.

Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia.

Berquet L, Valleron W, Grgurevic S, Quelen C, Zaki O, Quillet-Mary A, Davi F, Brousset P, Bousquet M, Ysebaert L.

Br J Haematol. 2016 Mar;172(5):819-23. doi: 10.1111/bjh.13544. Epub 2015 Jun 11. No abstract available.

PMID:
26095450
11.

Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.

Laprevotte E, Voisin G, Ysebaert L, Klein C, Daugrois C, Laurent G, Fournie JJ, Quillet-Mary A.

J Immunol. 2013 Oct 1;191(7):3634-40. doi: 10.4049/jimmunol.1300187. Epub 2013 Aug 30.

12.

Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia.

Laprevotte E, Ysebaert L, Klein C, Valleron W, Blanc A, Gross E, Laurent G, Fournié JJ, Quillet-Mary A.

Leuk Res. 2013 Apr;37(4):440-6. doi: 10.1016/j.leukres.2012.11.015. Epub 2012 Dec 20.

PMID:
23259986
13.

Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells.

Liffraud C, Quillet-Mary A, Fournié JJ, Laurent G, Ysebaert L.

Leuk Lymphoma. 2012 May;53(5):966-72. doi: 10.3109/10428194.2011.634041. Epub 2011 Dec 6.

PMID:
22023517
14.

Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study.

Laurent C, Müller S, Do C, Al-Saati T, Allart S, Larocca LM, Hohaus S, Duchez S, Quillet-Mary A, Laurent G, Brousset P, Valitutti S.

Blood. 2011 Nov 17;118(20):5371-9. doi: 10.1182/blood-2011-04-345777. Epub 2011 Aug 19.

15.

Cancer stem cells of differentiated B-cell malignancies: models and consequences.

Gross E, Quillet-Mary A, Ysebaert L, Laurent G, Fournie JJ.

Cancers (Basel). 2011 Mar 25;3(2):1566-79. doi: 10.3390/cancers3021566.

16.

B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.

Gross E, L'Faqihi-Olive FE, Ysebaert L, Brassac M, Struski S, Kheirallah S, Fournié JJ, Laurent G, Quillet-Mary A.

Leukemia. 2010 Nov;24(11):1885-92. doi: 10.1038/leu.2010.176. Epub 2010 Sep 9.

PMID:
20827287
17.

Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.

Ysebaert L, Gross E, Kühlein E, Blanc A, Corre J, Fournié JJ, Laurent G, Quillet-Mary A.

Leukemia. 2010 Jul;24(7):1310-6. doi: 10.1038/leu.2010.89. Epub 2010 May 13.

PMID:
20463751
18.

Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.

Capietto AH, Keirallah S, Gross E, Dauguet N, Laprévotte E, Jean C, Gertner-Dardenne J, Bezombes C, Quillet-Mary A, Poupot M, Ysebaert L, Laurent G, Fournié JJ.

Curr Drug Targets. 2010 Jul;11(7):790-800. Review.

PMID:
20370648
19.

Rituximab inhibits B-cell receptor signaling.

Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, Fournié JJ, Laurent G, Bezombes C.

Blood. 2010 Feb 4;115(5):985-94. doi: 10.1182/blood-2009-08-237537. Epub 2009 Nov 17.

20.

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.

Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, Cendron D, Gross E, Lepage JF, Quillet-Mary A, Ysebaert L, Laurent G, Sicard H, Fournié JJ.

Blood. 2009 May 14;113(20):4875-84. doi: 10.1182/blood-2008-08-172296. Epub 2009 Mar 10.

21.

PKCzeta protects against UV-C-induced apoptosis by inhibiting acid sphingomyelinase-dependent ceramide production.

Charruyer A, Jean C, Colomba A, Jaffrézou JP, Quillet-Mary A, Laurent G, Bezombes C.

Biochem J. 2007 Jul 1;405(1):77-83.

22.

Granzyme B induction signalling pathway in acute myeloid leukemia cell lines stimulated by tumor necrosis factor alpha and Fas ligand.

Guilloton F, Jean C, de Thonel A, Laurent G, Quillet-Mary A.

Cell Signal. 2007 Jun;19(6):1132-40. Epub 2007 Jan 3.

PMID:
17258890
23.

UVA induces granzyme B in human keratinocytes through MIF: implication in extracellular matrix remodeling.

Hernandez-Pigeon H, Jean C, Charruyer A, Haure MJ, Baudouin C, Charveron M, Quillet-Mary A, Laurent G.

J Biol Chem. 2007 Mar 16;282(11):8157-64. Epub 2007 Jan 15.

24.

Human keratinocytes acquire cellular cytotoxicity under UV-B irradiation. Implication of granzyme B and perforin.

Hernandez-Pigeon H, Jean C, Charruyer A, Haure MJ, Titeux M, Tonasso L, Quillet-Mary A, Baudouin C, Charveron M, Laurent G.

J Biol Chem. 2006 May 12;281(19):13525-32. Epub 2006 Mar 8.

25.

Mithramycin A activates Fas death pathway in leukemic cell lines.

Leroy I, Laurent G, Quillet-Mary A.

Apoptosis. 2006 Jan;11(1):113-9.

PMID:
16374547
26.

TNFalpha stimulates NKG2D-mediated lytic activity of acute myeloid leukemic cells.

Guilloton F, de Thonel A, Jean C, Demur C, Mansat-De Mas V, Laurent G, Quillet-Mary A.

Leukemia. 2005 Dec;19(12):2206-14.

PMID:
16239914
27.

Protein kinase C zeta associates with death inducing signaling complex and regulates Fas ligand-induced apoptosis.

Leroy I, de Thonel A, Laurent G, Quillet-Mary A.

Cell Signal. 2005 Sep;17(9):1149-57. Epub 2005 Feb 17.

PMID:
15993755
28.

hMutS alpha is protected from ubiquitin-proteasome-dependent degradation by atypical protein kinase C zeta phosphorylation.

Hernandez-Pigeon H, Quillet-Mary A, Louat T, Schambourg A, Humbert O, Selves J, Salles B, Laurent G, Lautier D.

J Mol Biol. 2005 Apr 22;348(1):63-74.

PMID:
15808853
29.

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains.

Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Müller S, Jaffrézou JP, Laurent G.

Blood. 2004 Aug 15;104(4):1166-73. Epub 2004 May 4.

30.

Overexpression of protein kinase Czeta confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation.

Bezombes C, de Thonel A, Apostolou A, Louat T, Jaffrézou JP, Laurent G, Quillet-Mary A.

Mol Pharmacol. 2002 Dec;62(6):1446-55.

PMID:
12435813
31.

Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin.

Mas VM, Hernandez H, Plo I, Bezombes C, Maestre N, Quillet-Mary A, Filomenko R, Demur C, Jaffrézou JP, Laurent G.

Blood. 2003 Feb 15;101(4):1543-50. Epub 2002 Oct 24.

32.

Protein kinase C-zeta overexpression induces erythroid phenotype in the monocytic leukaemia cell line U937.

Mansat-De Mas V, de Thonel A, Gaulin V, Demur C, Laurent G, Quillet-Mary A.

Br J Haematol. 2002 Aug;118(2):646-53.

PMID:
12139760
33.

Role of protein kinase C zeta isoform in Fas resistance of immature myeloid KG1a leukemic cells.

de Thonel A, Bettaïeb A, Jean C, Laurent G, Quillet-Mary A.

Blood. 2001 Dec 15;98(13):3770-7.

34.

Oxidative stress-induced activation of Lyn recruits sphingomyelinase and is requisite for its stimulation by Ara-C.

Bezombes C, Plo I, Mansat-De Mas V, Quillet-Mary A, Nègre-Salvayre A, Laurent G, Jaffrézou JP.

FASEB J. 2001 Jul;15(9):1583-5. No abstract available.

PMID:
11427493
35.

Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin.

Bruno AP, Lautier D, d'Orgeix AT, Laurent G, Quillet-Mary A.

Blood. 2000 Sep 1;96(5):1914-20.

36.

Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin.

Mansat-de Mas V, Bezombes C, Quillet-Mary A, Bettaïeb A, D'orgeix AD, Laurent G, Jaffrézou JP.

Mol Pharmacol. 1999 Nov;56(5):867-74.

PMID:
10531389
37.

Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis.

Bettaïeb A, Plo I, Mansat-De Mas V, Quillet-Mary A, Levade T, Laurent G, Jaffrézou JP.

Mol Pharmacol. 1999 Jan;55(1):118-25.

PMID:
9882705
38.

Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis.

Quillet-Mary A, Jaffrézou JP, Mansat V, Bordier C, Naval J, Laurent G.

J Biol Chem. 1997 Aug 22;272(34):21388-95.

39.

Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines.

Quillet-Mary A, Mansat V, Duchayne E, Come MG, Allouche M, Bailly JD, Bordier C, Laurent G.

Leukemia. 1996 Mar;10(3):417-25.

PMID:
8642856
40.

Further characterization of CD82/IA4 antigen (type III surface protein): an activation/differentiation marker of mononuclear cells.

Lebel-Binay S, Gil ML, Lagaudriere C, Miloux B, Marchiol-Fournigault C, Quillet-Mary A, Lopez M, Fradelizi D, Conjeaud H.

Cell Immunol. 1994 Apr 1;154(1):468-83.

PMID:
7510585
41.

Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.

Quillet-Mary A, Cavarec L, Kermarrec N, Marchiol-Fournigault C, Gil ML, Conjeaud H, Fradelizi D.

Int J Cancer. 1991 Feb 1;47(3):473-9.

PMID:
1704356
42.

An improved double fluorescence flow cytometry method for the quantification of killer cell/target cell conjugate formation.

Cavarec L, Quillet-Mary A, Fradelizi D, Conjeaud H.

J Immunol Methods. 1990 Jul 3;130(2):251-61.

PMID:
2197333

Supplemental Content

Loading ...
Support Center